Mutant and curli-producing E. coli enhance the disease phenotype in a hSOD1-G93A mouse model of ALS
- PMID: 37045868
- PMCID: PMC10097672
- DOI: 10.1038/s41598-023-32594-5
Mutant and curli-producing E. coli enhance the disease phenotype in a hSOD1-G93A mouse model of ALS
Abstract
The gut microbiome is a potential non-genetic contributing factor for Amyotrophic Lateral Sclerosis. Differences in gut microbial communities have been detected between ALS subjects and healthy controls, including an increase in Escherichia coli in ALS subjects. E. coli and other gram-negative bacteria produce curli proteins, which are functional bacterial amyloids. We examined whether long-term curli overexposure in the gut can exacerbate the development and progression of ALS. We utilized the slow-developing hSOD1-G93A mouse model of ALS with their C57BL/6J WT littermate controls, including males and females, with a total of 91 animals. These mice were on a normal chow diet and fed curli-producing or curli-nonproducing (mutant) E. coli in applesauce (vehicle) 3 times/week, from 1 through 7 months of age. Male hSOD1 mice demonstrated gradual slowing in running speed month 4 onwards, while females exhibited no signs of locomotive impairment even at 7 months of age. Around the same time, male hSOD1 mice showed a gradual increase in frequency of peripheral CD19+ B cells. Among the male hSOD1 group, chronic gut exposure to curli-producing E. coli led to significant shifts in α- and β-diversities. Curli-exposed males showed suppression of immune responses in circulation, but an increase in markers of inflammation, autophagy and protein turnover in skeletal muscle. Some of these markers were also changed in mutant E. coli-exposed mice, including astrogliosis in the brainstem and demyelination in the lumbar spinal cord. Overall, chronic overexposure to a commensal bacteria like E. coli led to distant organ pathology in our model, without the presence of a leaky gut at 6 months. Mechanisms underlying gut-distant organ communication are of tremendous interest to all disciplines.
© 2023. The Author(s).
Conflict of interest statement
Robert P. Friedland is a stockholder in Axial Therapeutics. ZK, JDM, RAS, JM, SMS, ED, DAB, LJB, and LJS have no competing interests to declare.
Figures







Similar articles
-
Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.Int J Mol Sci. 2017 Aug 1;18(8):1666. doi: 10.3390/ijms18081666. Int J Mol Sci. 2017. PMID: 28763002 Free PMC article.
-
Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells.Cell Transplant. 2009;18(10):1171-81. doi: 10.3727/096368909X12483162197123. Epub 2009 Aug 5. Cell Transplant. 2009. PMID: 19660174
-
Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.Br J Pharmacol. 2017 Apr;174(8):689-699. doi: 10.1111/bph.13730. Epub 2017 Mar 3. Br J Pharmacol. 2017. PMID: 28128456 Free PMC article.
-
Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.Neurobiol Dis. 2000 Dec;7(6 Pt B):623-43. doi: 10.1006/nbdi.2000.0299. Neurobiol Dis. 2000. PMID: 11114261
-
Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers.Amyotroph Lateral Scler. 2011 Mar;12(2):79-86. doi: 10.3109/17482968.2010.550626. Epub 2011 Jan 17. Amyotroph Lateral Scler. 2011. PMID: 21241159 Review.
Cited by
-
Microbiome-based therapies for Parkinson's disease.Front Nutr. 2024 Nov 6;11:1496616. doi: 10.3389/fnut.2024.1496616. eCollection 2024. Front Nutr. 2024. PMID: 39568727 Free PMC article. Review.
-
Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases.Molecules. 2025 Feb 4;30(3):687. doi: 10.3390/molecules30030687. Molecules. 2025. PMID: 39942791 Free PMC article. Review.
-
Neurodegenerative diseases: from gut-brain axis to brain microbiome.Front Aging Neurosci. 2023 May 19;15:1171955. doi: 10.3389/fnagi.2023.1171955. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37273657 Free PMC article. No abstract available.
-
Gut Microbiota as a Modifier of Huntington's Disease Pathogenesis.J Huntingtons Dis. 2024;13(2):133-147. doi: 10.3233/JHD-240012. J Huntingtons Dis. 2024. PMID: 38728199 Free PMC article. Review.
-
Microbial amyloids in neurodegenerative amyloid diseases.FEBS J. 2025 Mar;292(6):1265-1281. doi: 10.1111/febs.17023. Epub 2023 Dec 11. FEBS J. 2025. PMID: 38041542 Free PMC article. Review.
References
-
- Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS. Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103(627–641):e627. doi: 10.1016/j.neuron.2019.05.035. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous